INTELLIA THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
INTELLIA THERAPEUTICS, INC. (NTLA) reported Increase (Decrease) in Contract with Customer, Liability of -$7.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$630.00K.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$6.66M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$13.98M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$4.91M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$28.11M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was -$22.08M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$2.78M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$63.46M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$630.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$7.29M 10-Q · filed 2026-08-06 | -$21.27M derived: sum of 3 quarters · filed 2026-08-06 | -$26.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$6.66M 10-Q · filed 2026-05-11 | -$20.64M derived: sum of 2 quarters · filed 2026-05-11 | -$25.55M derived: sum of 3 quarters · filed 2026-05-11 | -$29.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$13.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$18.89M derived: sum of 2 quarters · filed 2026-02-26 | -$23.02M derived: sum of 3 quarters · filed 2026-08-06 | -$28.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$4.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$9.04M derived: sum of 2 quarters · filed 2026-08-06 | -$14.13M 10-Q · filed 2025-11-06 | -$19.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$9.22M 10-Q · filed 2026-08-06 | -$15.07M derived: sum of 3 quarters · filed 2026-08-06 | -$20.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$5.09M 10-Q · filed 2026-05-11 | -$10.94M derived: sum of 2 quarters · filed 2026-05-11 | -$16.41M derived: sum of 3 quarters · filed 2026-05-11 | -$21.80M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$11.32M derived: sum of 2 quarters · filed 2026-02-26 | -$16.71M derived: sum of 3 quarters · filed 2026-02-26 | -$22.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$5.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$10.86M derived: sum of 2 quarters · filed 2025-11-06 | -$16.23M 10-Q · filed 2025-11-06 | $18.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$5.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$10.76M 10-Q · filed 2025-08-07 | $24.17M derived: sum of 3 quarters · filed 2026-02-26 | $15.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$5.37M 10-Q · filed 2025-05-08 | $29.56M derived: sum of 2 quarters · filed 2026-02-26 | $20.77M derived: sum of 3 quarters · filed 2026-02-26 | $6.42M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $34.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.14M derived: sum of 2 quarters · filed 2026-02-26 | $11.79M derived: sum of 3 quarters · filed 2026-02-26 | -$2.78M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$8.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$23.14M derived: sum of 2 quarters · filed 2024-11-07 | -$37.70M 10-Q · filed 2024-11-07 | -$54.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$14.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$28.92M 10-Q · filed 2024-08-08 | -$45.64M derived: sum of 3 quarters · filed 2025-02-27 | -$62.28M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$14.57M 10-Q · filed 2024-05-09 | -$31.29M derived: sum of 2 quarters · filed 2025-02-27 | -$47.93M derived: sum of 3 quarters · filed 2025-02-27 | -$64.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$16.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$33.37M derived: sum of 2 quarters · filed 2025-02-27 | -$49.47M derived: sum of 3 quarters · filed 2025-02-27 | -$63.46M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$16.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$32.74M derived: sum of 2 quarters · filed 2023-11-09 | -$46.74M 10-Q · filed 2023-11-09 | -$61.11M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$16.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$30.10M 10-Q · filed 2023-08-03 | -$44.47M derived: sum of 3 quarters · filed 2024-02-22 | -$50.27M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$13.99M 10-Q · filed 2023-05-04 | -$28.36M derived: sum of 2 quarters · filed 2024-02-22 | -$34.17M derived: sum of 3 quarters · filed 2024-02-22 | -$39.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$14.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$20.18M derived: sum of 2 quarters · filed 2024-02-22 | -$25.80M derived: sum of 3 quarters · filed 2024-02-22 | -$31.36M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$5.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$11.43M derived: sum of 2 quarters · filed 2022-11-03 | -$16.99M 10-Q · filed 2022-11-03 | -$22.67M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$5.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$11.18M 10-Q · filed 2022-08-04 | -$16.86M derived: sum of 3 quarters · filed 2023-02-23 | -$37.93M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$5.56M 10-Q · filed 2022-05-05 | -$11.24M derived: sum of 2 quarters · filed 2023-02-23 | -$32.31M derived: sum of 3 quarters · filed 2023-02-23 | $42.71M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$5.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$26.75M derived: sum of 2 quarters · filed 2023-02-23 | $48.27M derived: sum of 3 quarters · filed 2023-02-23 | $45.12M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$21.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $53.95M derived: sum of 2 quarters · filed 2021-11-04 | $50.80M 10-Q · filed 2021-11-04 | $44.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $75.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $71.87M 10-Q · filed 2021-08-05 | $65.53M derived: sum of 3 quarters · filed 2022-02-24 | $58.52M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$3.15M 10-Q · filed 2021-05-06 | -$9.48M derived: sum of 2 quarters · filed 2022-02-24 | -$16.50M derived: sum of 3 quarters · filed 2022-02-24 | -$23.43M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$13.35M derived: sum of 2 quarters · filed 2022-02-24 | -$20.28M derived: sum of 3 quarters · filed 2022-02-24 | -$27.12M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$7.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$13.95M derived: sum of 2 quarters · filed 2020-11-05 | -$20.79M 10-Q · filed 2020-11-05 | -$11.12M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$6.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$13.77M 10-Q · filed 2020-08-06 | -$4.10M derived: sum of 3 quarters · filed 2021-02-26 | -$8.70M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$6.84M 10-Q · filed 2020-05-07 | $2.83M derived: sum of 2 quarters · filed 2021-02-26 | -$1.77M derived: sum of 3 quarters · filed 2021-02-26 | -$6.30M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $9.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $5.07M derived: sum of 2 quarters · filed 2021-02-26 | $538.00K derived: sum of 3 quarters · filed 2021-02-26 | -$3.94M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$4.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$9.13M derived: sum of 2 quarters · filed 2019-10-31 | -$13.60M 10-Q · filed 2019-10-31 | -$13.29M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$4.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$9.01M 10-Q · filed 2019-08-01 | -$8.70M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2018-03-31 | -$4.47M 10-Q · filed 2019-05-02 | -$4.16M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$12.99M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | -$13.30M 10-Q · filed 2018-10-31 | |||
| 2016-12-31 | $67.97M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |